Bispecific Platforms: OmniFlic® and OmniClic®
OmniAb’s bispecific IgG platforms provide an efficient and effective means of finding high-quality human antibodies that are capable of binding to two different antigens at the same time. Biopharmaceutical companies that use these technologies to generate bispecific antibodies can develop treatments for a wide range of conditions. They utilize common light chains for antibody generation to simplify the process. As your therapeutic partner, OmniAb delivers flexible, high-quality options to facilitate your discovery processes, giving you multiple paths to revealing the ideal candidate for your efforts. To learn more about these platforms, reach out and speak with one of our representatives today.
About OmniFlic: A Common Light Chain Transgenic Rat
OmniFlic was designed based on the OmniRat experience and launched in 2014. It features:
- The same heavy chain transgenes as OmniRat
- A single rearranged VkJk light chain for the development of bispecific, fully human antibodies
- Antibodies that comprise a single germline Vk sequence and can be generated through comprehensive analysis of the heavy chain repertoires
Like OmniClic, OmniFlic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.
About the OmniClic transgenic chicken
The OmniClic transgenic chicken was specifically developed to facilitate the generation of bispecific antibodies. It was launched in 2019.
OmniClic was engineered to:
- Focus sequence diversity on the CDRs of the VH domain
- Express the VH3-23 and VK3-15 light chains, with a modified light chain transgene to minimize diversification
- Generate diverse, high-quality affinity-matured antibodies
Like OmniFlic, OmniClic expresses the VK3-15 light chain so antibodies generated using these platforms can be combined to form a bispecific human antibody.